Background/Aims: IL-1β is an important mediator of "inflammation-cancer" transformation through IL-1β/NF-κB/COX-2/HIF-1α signaling pathway, whereas certain portion of patients with lung adenocarcinoma (LUAD) still suffer from rapid tumor progression in clinical practice, indicating the occurrence of potential bypass. Methods: Real-time polymerase chain reaction was applied to examine the expressions of mir-144-3p, WT1, NF-κB, COX2 and HIF-1α at the mRNA level in 127 LUAD samples and corresponding adjacent tissues. miR-144-3p mimic and antagormiR were used to trigger activation and suppression of miR-144-3p in A549 cells, respectively. MTT assay and Western blotting analysis were carried out to evaluate the cell proliferation. Stable clones with over-expression or knockdown of WT1 were generated with plasmid or shRNA by lentiviral vector technology in H1568 and H1650 NSCLC cell lines, respectively. Dual luciferase reporter assay was performed to validate the effect of miR-144-3p on WT1D. Xenograft model was established for in vivo experiment, and TCGA data were extracted for validation. Results: miR-144-3p could suppress the WT1D expression at the post-transcriptional level, hence regulating cell proliferation in LUAD. WT1 and COX-2 were independent prognostic factors of LUAD patients. In addition, inhibition of IL-1β/miR-144-3p/WT1D and IL-1β/NF-κB/COX-2/HIF-1α pathways using miR-144-3p mimic and Celecoxib, 
Introduction
Lung cancer remains the leading cause of cancer-related death worldwide, and its case number is constantly increasing [1] . Great efforts have been made to increase clinical benefits, and promising results have been achieved in patients harboring driver mutations and immunological specificity using targeted and immunotherapies, respectively. Non-small-cell lung cancer (NSCLC) accounts for about 85% of lung cancer, of which lung adenocarcinoma (LUAD) accounts for 60% [2] .
Chronic inflammation and infection have been established as pivotal factors of carcinogenesis [3] [4] [5] [6] [7] . Although evidence has demonstrated significant relationship between tumor development and focal (systemic) inflammation in LUAD [8] , the underlying mechanism remains largely unexplored. Interleukin-1 beta (IL-1β) is a member of the IL-1 cytokine family that is produced by activated macrophages as a pro-protein and processed to its active form by caspase 1 [9] . The induction of cyclooxygenase-2 (PTGS2/COX2) by IL-1β in the central nervous system (CNS) contributes to inflammatory pain hypersensitivity [10] . Our previous study has demonstrated that in LUAD patients, the serum IL-1β level is correlated with miR-144-3p, and such correlation may affect the miR-144-3p expression at the transcriptional level. Both of IL-1β and miR-144-3p are independent risk factors for prognosis of LUAD. In addition, IL-1β and miR-144-3p may mediate inflammation-promoted proliferation in LUAD patients [11] . Based on above-mentioned findings, we wondered via which target gene IL-1β and miR-144-3p regulated the proliferation and how IL-1β/miR-144-3p pathway was linked to IL-1β/NF-κB/COX-2/HIF-1α pathway.
In this study, we found that WT1D was a potential target of miR-144-3p, and both in vitro and in vivo experiments confirmed that IL-1β and miR-144-3p regulated the cell proliferation in LUAD through WT1D. WT1 and COX-2 were prognostic factors of LUAD patients according to the Cancer Genome Atlas (TCGA) database. In addition, simultaneous blockade of both IL-1β/miR-144-3p/WT1D and IL-1β/NF-κB/COX-2/HIF-1α pathways might have synergistic suppressive effect on cell proliferation in LUAD.
Materials and Methods

Patients, samples, cell lines and animals
A total of 127 randomly selected LUAD patients were enrolled in the present study. Specimens were collected from the Third Affiliated Hospital of Soochow University (Changzhou, China) during biopsy and surgery, and freshly collected samples were immediately frozen in liquid nitrogen or fixed in formaldehyde. Informed consent was obtained from each participant, and our study was approved by the Ethics Committee of Human Experimentation. All specimens were histologically and blindly classified by two professional pathologists according to the national NCCN guidelines for NSCLC.
The human NSCLC cell line A549 was obtained from American Type Culture Collection (ATCC, USA) and cultured according to the guideline.
A total of 20 4-week-old Balb/c nu/nu mice were purchased from Model Animal Research Center of Nanjing University, China. Animals were bred in an SPF-grade animal breeding facility of Soochow University.
TCGA database
The expression profiles of WT1, NF-κB, COX-2 and HIF-1α as well as clinical information of LUAD samples were obtained from TCGA database, including 452 LUAD patients. The K-means clustering analysis (K = 2) was carried out to categorize the patients into two groups based on expressions of WT1, NF-κB, 
Western blotting analysis
Total proteins were extracted using CHAPS lysis buffer. Equal amounts of proteins were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto polyvinylidene fluoride (PVDF) membrane. Blots were blocked in 4% dry milk at room temperature for 1 h, followed by incubation with different primary antibodies [anti-WT1 (6F-H2) 
MTT assay
Cell proliferation was determined using Vybrant MTT Cell Proliferation Assay Kit (Invitrogen, catalog No. V13154). Cells were collected at 0, 24, 48 and 72 h after Celecoxib exposure and miR-144-3p mimic transfection. Absorbance at a wavelength of 570 nm was determined by a spectrometer. The experiment was performed in triplicates.
Tumorigenicity in nude mice
To investigate synergistic effect of blockade of IL-1β/miR-144-3p/WT1D and IL-1β/NF-κB/COX-2/ HIF-1α pathways on tumor growth, xenograft model was established in 4-week-old Balb/c nu/nu mice for in vivo experiment. Briefly, A549 cells were trypsinized, resuspended in 100 μL PBS containing 50 μL Matrigel 
Immunohistochemistry (IHC)
Tissues were fixed in 4% paraformaldehyde and cut from paraffin-embedded block to 5 μm sections. After dewaxing with xylene and rehydration in a graded series of ethanol, the slides were heated in the autoclave for 3 min using citrate buffer (pH 6.0) and incubated with primary antibodies against NF-κB Immunostaining was scored by two pathologists using H-score method.
Lentiviral production and transduction WT1D gene was synthesized (purchased from Genscript, China) with restrictive digestion using Mlu I, subcloned into pLV-GFP plasmid and named pLV-GFP-WT1. To generate plasmid expressing WT1-shRNA, double-stranded oligonucleotides were cloned into pLL3.7 vector and named pLL3.7-shWT1. The sequence of WT1-shRNA was acTCAGGGTTACAGCACGGTCttcaagagaGACCGTGCTGTAACCCTGAttttttc. The uppercase letters represent WT1 specific sequence, and lowercase letters represent hairpin sequences. Recombinant lentivirus was generated from 293T cells using calcium phosphate precipitation. A549 cells were transfected with lentivirus using polybrene (8 μg/mL).
Luciferase reporter assay
A dual-luciferase reporter assay was performed to investigate the transcriptional regulation of WT1D by miR-144-3p. The 3' UTR of WT1D containing miR-144-3p binding site (UACUGUA) was synthesized artificially and named WT1D 3' UTR. The 3' UTR with the mutated binding site (GCACGCA) was also synthesized and named WT1D 3'UTR-mut (Fig. 1E ). Products were validated via agarose gel electrophoresis and cloned into the luciferase reporter vector (Promega, Madison, WI). A549 cells were seeded into 24-well plates and co-transfected with miR-144-3p mimic (marked as ''á''), miR-144-3p antagoR (marked as ''â'') or control miRNA (marked as ''一') respectively and luciferase reporter vector using Lipofectamine™ 2000 (Invitrogen, catalog No. 11668019) following the manufacturer's instructions. At 0, 6, 12, 24 and 48 h after incubation, firefly and Renilla luciferase activities were determined with the dual luciferase reporter assay system (Promega, catalog No. E1910). All results were obtained from three independent experiments.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (version 5.01; GraphPad Software) and SPSS (version 17, SPSS Inc) statistical software. The Student's t-test and paired t-test were used to analyze significance between independent groups and paired materials, respectively. The χ2 test was used to assess the significance of observed differences in proportions except when the cell size was less than 5 (Fisher's exact tests). Survival curves were made using the Kaplan-Meier method and compared using the log-rank test. All variables that achieved significance at P ≤ 0.05 in univariate analyses were enrolled in multivariate Cox's proportional hazard model. P ≤ 0.05 was considered as statistically significant unless otherwise specified.
Results
Our previous work has demonstrated that in LUAD patients, the IL-1β level is correlated with miR-144-3p, and such correlation can affect the miR-144-3p expression at the transcriptional level. Both of them are associated with prognosis and independent risk factors for LUAD patients. In addition, IL-1β may promote cell proliferation via suppression of miR-144-3p. Via web tool http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/ promo.cgi? dirDB=TF_8.3&calledBy=alggen, one potential miR-144-3p binding site has been predicted Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry in WT1D 3' UTR. Moreover, IL-1β-mediated up-regulation of HIF-1α via an NF-κB/COX-2 pathway has been identified, and an IL-1β/ NF-κB/COX-2/HIF-1α pathway may be a critical link between inflammation and oncogenesis. As a result, we hypothesized that a potential IL-1β/miR-144-3p/WT1D pathway might be involved in proliferative regulation and crosstalk with IL-1β/ NF-κB/COX-2/HIF-1α pathway of LUAD.
WT1 expression is suppressed by miR-144-3p at the post-transcriptional level miR-144-3p mimic or antagomiR could suppress or enhance the WT1 expression at the protein level, respectively (Fig. 1A&B) . IL-1β suppressed miR-144-3p and enhanced WT1 expression (Fig. 1A, B&D) . Over-expression or silencing of WT1 by plv-GFP-WT1D or pLL3.7-shWT1 displayed limited effect on miR-144-3p, respectively (Fig. 1C) . The luciferase activity in A549 cells over-expressing miR-144-3p was decreased (Fig. 1F) , while it was increased after suppression of miR-144-3p (Fig. 1G) . The enhancive (attenuative) effect of miR-144-3p on WT1 3' UTR was crippled when WT1 3' UTR was mutated (Fig. 1H) .
miR-144-3p suppresses tumor proliferation and had synergistic effect on COX-2 inhibition
In vitro study showed that Celecoxib and miR-144-3p mimic both suppressed cell proliferation (P < 0.001), and their combination even more significantly suppressed cell proliferation compared with the mono-treatment (P < 0.0001) ( Fig.  2A) . WT1 expression was increased when IL-1β/NF-κB/COX-2/HIF-1α pathway was suppressed by Celecoxib. Similarly, COX-2 expression was increased after exposure to miR-144-3p mimic, indicating that IL-1β/ NF-κB/COX-2/HIF-1α and IL-1β/miR-144-3p/WT1D pathways existed downstream of IL-1β (Fig. 2B) . PCNA protein was also suppressed by Celecoxib and miR-144-3p over-expression, which was consistent with MTT result (Fig. 2B) . In vivo experiment exhibited that the combination therapy suppressed subcutaneous implant most significantly (Fig. 2C&D) . Fig. 3 shows that positive staining of NF-κB, COX-2, HIF-1α and WT1 was detected in all patients.
Prognosis evaluation between different groups of LUAD patients
Based on TCGA database, patients with low WT1 (Fig. 4A ) and high COX-2 ( Fig. 4C ) levels showed better prognosis compared with their counterparts, respectively, which validated our findings. Besides, patients with high HIF-1α (Fig. 4D ) level also showed longer survival. Fig. 1 . miR-144-3p suppresses WT1 expression at the post-transcriptional level. The expression of WT1 at the protein level was significantly downregulated when miR-144-3p expression was enhanced by mimic, while it was up-regulated when miR-144-3p was suppressed by antagomir (B). IL-1β exposure could suppress miR-144-3p, but enhance WT1 expression (A, B&D). miR-144-3p expression at the mRNA level varied slightly after WT1 over-expression or silencing by plv-GFP-WT1D or pLL3.7-shWT1, respectively (C). The structures of wild-type or mutated WT1D 3' UTR (WT1D 3' UTR & WT1D 3' UTR-mut) were synthesized artificially and illustrated (E). The luciferase activity in A549 cells was deceased after miR-144-3p over-expression (F) and increased after suppression (G). The enhancive (attenuative) effect of miR-144-3p on WT1 3' UTR was crippled when WT1 3' UTR was mutated (H).
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Patients with low WT1 level (Fig.  5A ), high COX-2 level (Fig. 5C ), early stage (stage 1-2) (Fig. 5E ) and past history of TKI therapy (Fig. 5F ) showed better prognosis compared with those with their counterparts (P < 0.001), whereas no significant differences in prognosis were observed between patients with high and low levels of NF-κB (P = 0.997) (Fig. 5B) or HIF-1α (P = 0.534) (Fig. 5D) .
By χ2 test, we confirmed that WT1 was correlated with clinical stage and TKI treatment in LUAD patients (Table 1) . Univariate analysis showed that clinical stage, TKI therapy, WT1 level and COX-2 level were significant prognostic factors, while age, gender, smoking status, NF-κB and HIF-1α displayed no statistical differences ( Table 2) . As an association was determined between WT1 level and clinical stage, and two separate multivariate models (WT1 and clinical stage) were run to avoid pathways were detected via IHC. NF-κB, COX-2, HIF-1α and WT1D were all negative in patient C6, while they were all positive in patients A8 and C8. In patient C2, NF-κB and WT1D were positive, while COX-2 and HIF-1α were negative. (Table 2) .
Discussion
Serum IL-1β level has been correlated with miR-144-3p, and such correlation affects the miR-144-3p expression at the transcriptional level. Both of them are independent risk factors for prognosis of LUAD [11] . In the present study, we demonstrated that a de novo IL-1β/miR-144-3p/WT1D axis was involved in proliferative regulation of LUAD. Such finding was also validated by clinical data from both LUAD patients and TCGA database. In addition, simultaneous blockade of both IL-1β/miR-144-3p/WT1D and IL-1β/NF-κB/COX-2/HIF-1α pathways might have synergistic effect on suppression of cell proliferation in LUAD. 2 ) (E) and past history of TKI therapy (F) showed better prognosis compared with those with their counterparts (P<0.001), whereas no significant differences in prognosis were observed between patients with high and low NF-κB (P = 0.997) (B) or HIF-1α levels (P = 0.534) (D). IL-1β has been identified as pivotal cytokine in inflammation initiation and an important mediator of the inflammatory response [9] . The induction of COX-2 by IL-1β in the CNS contributes to inflammatory pain hypersensitivity [10] . In tumor initiation and development, it has been proved that IL-1β can activate HIF-1α via NF-κB and COX-2, making it a signaling bridge between inflammation and malignancy [12] . COX-2 expression induced by IL-1β can be inhibited by nonsteroidal anti-inflammatory drugs (NSAIDs), such as synthetic COX-2 inhibitor "Celecoxib", leading to cancer cell apoptosis, which explains anti-cancer effect and mechanism of NSAIDs [13] . Besides, NSAIDs display certain therapeutic effect on solid tumors, including LUAD. Shin DM et al. have discovered that targeted therapy (Erlotinib) combined with Celecoxib can effectively block proliferation of tumor cells in G1 phase in head and neck malignancies [14] . Lyons TR et al. have demonstrated that COX-2 can promote lymphangiogenesis in postpartum breast carcinoma, thus increasing the risk of lymph node metastasis, and Celecoxib can effectively control lymphangiogenesis and improve its prognosis [15] . These findings suggest that IL-1β can mediate "inflammation to cancer" transformation through COX-2/HIF-1α, whereas NSAIDs can effectively suppress or postpone such process. Nevertheless, NVALT-4 trial has shown that Celecoxib does not prolong survival of NSCLC patients, and COX-2 is not an independent prognostic factor [16] . A certain portion of NSCLC patients can not benefit from NSAIDs, and they still suffer from rapid progression of tumor in clinical practice. Studies have confirmed that Celecoxib can promote epithelial-mesenchymal transition (EMT) of cancer cells, leading to increased metastatic risk [17] . Taken together, COX-2/HIF-1α signaling was probably not the only IL-1β downstream pathway to promote cancer. Accordingly, NSAIDs might promote tumor progression in certain cases.
Our previous studies have demonstrated that IL-1β and miR-144-3p are involved in regulation of LUAD cell proliferation, suggesting an miRNA-related signaling bypass, which may explain the reason why certain portion of patients barely benefit from COX-2 inhibitor. WT1D is a direct target of miR-144-3p, and it has been demonstrated to be an oncogene in NSCLC, promoting cell proliferation and cancer progression. Therefore, we identified that WT1D was an important downstream molecule of IL-1β and miR-144-3p that promote cell proliferation in LUAD [11] .
miRNA is involved in gene regulation and affects various cell biology processes, which is also commonly detected in occurrence and development of cancer [18] [19] [20] [21] . As a result, changes of miRNA expression or activity might have significant effect on cell fate. miR-144-3p is an newly identified miRNA that is involved in multiple steps of antimicrobial immunity and cancer development. miR-144-3p inhibits autophagy activation by targeting ATG4a, enhances BCG infection and provides potential targets for improved treatments [22] . In [23] . miR-144-3p may have an advanced regulatory role in gene expressions. When one of two signaling pathways is blocked or suppressed, the other's function may be compensatorily enhanced to maintain the overall stability. Synergistic inhibitory effect usually occurs when multiple blockades are applied for two or more individual signaling pathways, such as combined immunotherapy of PD-1 and CTLA-4 monoclonal antibodies [24, 25] . In the present scenario, the COX-2 expression at the protein level was markedly increased when IL-1β/miR-144-3p/WT1D pathway was suppressed by miR-144-3p mimic (Fig. 2B) .
Collectively, our findings enriched the mechanisms underlying IL-1β-mediated transformation of "inflammation-cancer", and provided the reason why NSAIDs owned dichotomous effect and strong evidence for miR-144-3p to be an LUAD marker.
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